

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	glycopyrrolate
Brand Name	Cuvposa™
Dosage Form(s)	1 mg/ 5 ml Oral Solution
Manufacturer	Medexus Pharmaceuticals Inc.
Submission Type	New Submission
Use Reviewed	For reducing drooling caused by certain health problems in patients 3 to 18 years of age.
Common Drug Review (CDR)	Yes, the CDR recommended: Do Not Reimburse. Visit the CDR website for more details: SR0613 Cuvposa - CDEC Final Recommendation June 26, 2020 for posting.pdf (cadth.ca)
Provincial Review	Cuvposa™ was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to list reduce chronic severe drooling in patients aged three to 18 years with neurologic conditions associated with problem drooling.
Drug Coverage Decision	Non-Benefit
Date	February 28, 2023

Reason(s)	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> • The drug demonstrated some advantage over placebo with respect to efficacy but it is unclear whether the changes observed in drooling represent a clinically meaningful improvement. • The main study for Cuvposa (Study FH-00-01) was only eight weeks long, which is insufficient to determine the long-term efficacy and potential adverse events of treatment for a chronic condition such as severe drooling. In addition, Study FH-00-01 compared Cuvposa to placebo, there are no comparative studies versus other treatment options used in Canada to reduce severe drooling such as botulinum toxin, and other anticholinergic drugs (e.g., atropine, benztropine). • The pan-Canadian Pharmaceutical Alliance (pCPA) and Business Management, were not involved in negotiations with the manufacturer for this product.
Other Information	

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.